Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1238951-37-5 | MDL No. : | MFCD08686668 |
Formula : | C11H22N2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | PGZCVLUQTJRRAA-IUCAKERBSA-N |
M.W : | 214.30 | Pubchem ID : | 24903577 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.91 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 68.12 |
TPSA : | 41.57 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.67 cm/s |
Log Po/w (iLOGP) : | 2.88 |
Log Po/w (XLOGP3) : | 1.32 |
Log Po/w (WLOGP) : | 0.84 |
Log Po/w (MLOGP) : | 1.15 |
Log Po/w (SILICOS-IT) : | 0.69 |
Consensus Log Po/w : | 1.38 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.8 |
Solubility : | 3.38 mg/ml ; 0.0158 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.79 |
Solubility : | 3.44 mg/ml ; 0.0161 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.6 |
Solubility : | 5.42 mg/ml ; 0.0253 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.08 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
2.1 g | With triethylamine; In dichloromethane; at 0 - 20℃; | To a stirred solution of 2,4,6-trichloro-8-fluoro-7-(2-fluoro-6- methoxyphenyl)quinazoline (2 g, 5.34 mmol) in DCM (2OmL) at 0 °C, TEA (1.08 g, 10.7 mmol) was added and then (2R,5S)-tert-butyl 2,5-dimethylpiperazine-1- carboxylatet (1.15 g, 5.34 mmol) in DCM (20 mL) was added slowly. The mixture was stirred at RT overnight. The mixture was partitioned between water (5OmL) and DCM(lOOmL X 2).The organic layer was concentrated in vacuo and the residue was purified by flash column chromatography on silica gel to afford the desired product 3-2 (2.1 g). ESI-MS m/z: 553 [M+H]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
51.8% | With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; | To a solution of 4,4'-(chloromethylene)bis(fluorobenzene) (200 mg, 0.838 mmol) in acetonitrile (20 mL) at room temperature were added tert-butyl (2S,5S)-2,5- dimethylpiperazine-1-carboxylate (198 mg, 0.922 mmol) and DIPEA (0.439 mL, 2.51 mmol). The reaction mixture was heated to 85 C overnight and concentrated under reduced pressure to yield residue. The residue was dissolved in DCM (100 mL) and washed with water (20 mL), brine (20 mL) and dried over sodium sulfate and (1115) concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography using 24 g flash column, eluting with 30 % EtOAc in petroleum ether. The fractions were concentrated under reduced pressure to yield tert-butyl (2S,5S)-4- (bis(4-fluorophenyl)methyl)-2,5-dimethylpiperazine-1-carboxylate (200 mg, 51.8 % yield); LCMS: m/z = 417.4 (M+H); rt 1.74 min. LCMS Method: Mobile phase A: (1116) Buffer: acetonitrile (95:5) Mobile phase B: Buffer: acetonitrile (5:95) Method: %B: 0 min-20 %:1.1min -90 %: 1.7 min-90 % Column: AQUITY UPLC BEH C18 (3.0 x 50 mm) 1.7 ^m, Flow: 0.7 mL/min. |
[ 960283-58-3 ]
(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride
Similarity: 0.98
[ 1017606-58-4 ]
(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate
Similarity: 0.98
[ 674792-07-5 ]
tert-Butyl 2,2-dimethylpiperazine-1-carboxylate
Similarity: 0.96
[ 259808-67-8 ]
tert-Butyl 3,3-dimethylpiperazine-1-carboxylate
Similarity: 0.96
[ 2061980-49-0 ]
tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride
Similarity: 0.96
[ 960283-58-3 ]
(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride
Similarity: 0.98
[ 1017606-58-4 ]
(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate
Similarity: 0.98
[ 674792-07-5 ]
tert-Butyl 2,2-dimethylpiperazine-1-carboxylate
Similarity: 0.96
[ 259808-67-8 ]
tert-Butyl 3,3-dimethylpiperazine-1-carboxylate
Similarity: 0.96
[ 2061980-49-0 ]
tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride
Similarity: 0.96
[ 960283-58-3 ]
(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride
Similarity: 0.98
[ 1017606-58-4 ]
(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate
Similarity: 0.98
[ 674792-07-5 ]
tert-Butyl 2,2-dimethylpiperazine-1-carboxylate
Similarity: 0.96
[ 259808-67-8 ]
tert-Butyl 3,3-dimethylpiperazine-1-carboxylate
Similarity: 0.96
[ 2061980-49-0 ]
tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride
Similarity: 0.96